维普期刊资源整合服务平台（V6.5）

78篇 您的检索式：作者名="GELMON KA"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Safety, pharmacoki- netics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors 显示文摘	BATIST G GELMON KA CHI KN	2009	Clin Cancer Res2009，15，2：	1
2	Phase Ⅰ and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks显示文摘	DAVIS AJ GELMON KA SIU LL	2003	Invest New Drugs2003，21，1：	1
3	Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy显示文摘	BASELGA J GELMON KA VERMA S	2010	J Clin Oncol2010，28，7：	1
4	Phas Ⅱ triai of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy显示文摘	Baselga J Gelmon KA Verma S et a/	2010	J C/in Oncol2010，28，7：	1
5	Phase II trial of pertuzumab and trastuzumabin patients with human epidermal growth factor receptor 2-pos it ivem et astatic breast cancer that progress ed duri ng prior trast uzumab therapy显示文摘	Baselga J Gelmon KA Verma S		0，，07：	1
6	Bone-targeted a- gents and skeletal-related events in breast cancer patients with- bone metastases:the state of the art显示文摘	Clemons M Gelmon KA Pritchard KI	2012	Curt Oncol2012，19，5：	1
7	Development and assessment of conven-tional and targeted drug combinations for use in the treatment of aggressive breast cancers 显示文摘	Waterhouse DN Gelmon KA Klasa R	2006	Curr Cancer Drug Targets2006，6，6：	1
8	Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trascuzumab therapy 显示文摘	Baselga J Gelmon KA Vema S	2010	J clin Oncol2010，28，7：	1
9	Phase I study of liposomal vincristine 显示文摘	GELMON KA TOLCHER A DIAB AR	1999	J Clin Oncol1999，17，2：	1
10	PhaseⅡtrial of pertuzum-ab and trastuzumab in patients with human epidermal growth fac-tor receptor 2-positive metastatic breast cancer that progressedduring prior trastuzumab therapy显示文摘	Baselga J Gelmon KA Verma S	2010	J Clin Oncol2010，28，：	1
11	A phase Ⅱ trial of a neoadjuvant platinum regimen for locally advanced breast cancer: Pathologic response, long-term follow-up, and correlation with biomarkers 显示文摘	Yerushalmi R Hayes MM Gelmon KA	2009	Clin Breast Cancer2009，9，3：	1
12	Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy 显示文摘	Baselga J Gelmon KA Verma S	2010	J Clin Oncol2010，28，7：	1
13	Phase II trial of pertuzumaband trastuzumab in patients with human epidermal growth factor re- ceptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy 显示文摘	Baselga J Gelmon KA Verma S	2010	J Clin Oncol2010，28，7：	1
14	Development and as- sessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers显示文摘	Waterhouse DN Gelmon KA Klasa R	2006	Curr Cancer Drug Targets2006，6，6：	1
15	Phase II trial of per- tuzumab and trastuzumab in patients with human epidermal growth factor receptor 2 - positive metastatic breast cancer that progressed during prior trastuzumab therapy显示文摘	Baselga J Gelmon KA Venna S	2010	J Clin Onco12010，28，7：	1
16	Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes 显示文摘	Yerushalmi R Gelmon KA Leung S	2012	Breast Cancer Res Treat2012，132，1：	1
17	Phase Ⅰ study of lipsomal vincristine 显示文摘	GELMON KA TOLCHER A DIAB AR	1999	J Clin Oncol1999，17，2：	1
18	A phase I and pharmacokinetik (PK) study of the human DNA methyltransferase (Metase) antisense oligodeoxynucleotide MG98 given as a 21-day continous infusion every 4 weeks显示文摘	Gelmon KA Moore MJ	2000	Proc Am Soc Clin Oncol2000，19，4：	1
19	A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130 显示文摘	Gelmon KA Belanger K Soulieres D	2005	Invest New Drugs2005，23，5：	1
20	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer,a phase 2,multicentre,open-label,non-randomised study显示文摘	Gelmon KA Tischkowitz M Mackay H		0，，09：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示